© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
June 19, 2019
In this article, we review the characteristics of the BRAF mutation and the evolving strategies for managing BRAF-mutant metastatic colorectal cancer.
January 31, 2019
Cancer Network spoke with Dr. Scott Kopetz about RNA-based subtyping and the challenge of spreading the word of the importance of biomarker testing in colorectal cancer.
January 23, 2017
This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.
November 18, 2008
Davies/Goldberg Article Reviewed. The complexity of treatment options that now exist for patients with newly diagnosed metastatic colorectal cancer has increased dramatically over the past decade.